Arthur Tzianabos, Director at Stoke Therapeutics, Inc. (STOK), sold 35,490 shares at $45.08 ($1.6M) on 2020-11-23, disclosed to the SEC on 2020-11-25.
Open-market sale of $1.6M STOK by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $45.08 | 4,300 | $194K | 11.8% |
| 2 | $45.97 | 10,196 | $469K | 28.6% |
| 3 | $45.97 | 10,196 | $469K | 28.6% |
| 4 | $46.85 | 5,294 | $248K | 15.1% |
| 5 | $46.85 | 5,294 | $248K | 15.1% |
| 6 | $47.61 | 210 |
| $10K |
| 0.6% |
| Total | $46.13 avg | 35,490 | $1.6M | 100% |
| Filing → |
| FIXX | SELL | 2024-02-15 | $7K | — | Filing → |
| FIXX | SELL | 2023-01-11 | $15K | — | Filing → |
| FIXX | SELL | 2022-01-12 | $20K | — | Filing → |